Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02BLD
|
|||
| Former ID |
DNCL002269
|
|||
| Drug Name |
Oprozomib
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9] | Phase 2 | [1] | |
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1/2 | [2] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Preclinical | [4] | ||
| Company |
Onyx Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H32N4O7S
|
|||
| Canonical SMILES |
CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C
|
|||
| InChI |
1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
|
|||
| InChIKey |
SWZXEVABPLUDIO-WSZYKNRRSA-N
|
|||
| CAS Number |
CAS 935888-69-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proteasome (PS) | Target Info | Modulator | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01832727) Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317) | |||
| REF 5 | A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.